IRVINE, California, May 26, 2017 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has received U.S. Federal Government clearance to receive U.S. Federal Government contracts.
Tag Archives: Allen Herman
CBIS Ramps Up Production and Releases More New Products to Meet the Substantial Requests From Self-Medicating Patients Across the Country as it Highlights Moonlight Cannabis as its Newest Spotlight Dispensary for the Month of April 2017
IRVINE, Calif., March 27, 2017 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce that it has substantially increased its production for its self-medicating patient product line distributed through cannabis dispensaries in California.
Cannabis Science Senior Executives to Co-Chair Special Session and Deliver a Keynote Speech at the Global Health Catalyst Summit at Harvard Medical School
IRVINE, Calif., March 1, 2017 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce that its President, CEO and Co-Founder, Raymond C. Dabney, will be a keynote speaker and panelist at the Global Health Catalyst (GHC) Summit at Harvard Medical School on April 28-30, 2017.
Cannabis Science Orders Multiple Greenhouse Structures for its 2nd Pilot 33,000 Sq. Ft. Drug Development Facility Buildout in Douglas County, Nevada
IRVINE, Calif., Dec. 21, 2016 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medications, has started work on its second 33,000 sq. ft. pilot cannabinoid drug development and manufacturing facility in Douglas County, Nevada.
Cannabis Science and the Research Foundation Begins Protocols for California Legal Patients to Receive the New CBIS MDI Rescue Inhaler for Its First Observational Study Intending to Lead Into Clinical Trials
IRVINE, Calif., Aug. 12, 2016 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is happy to announce the intent to seek out 20 - 25 potential candidates suffering from Asthma/COPD and other critical ailments.
Cannabis Science Orders First Batch Inhalation Medication and Adds CBIS MDI Rescue Inhaler for Asthma/COPD via Nebulizer, Targeting 25+ Legal States, and National Market Variables
IRVINE, Calif., Aug. 11, 2016 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis based medicines, is happy to announce their first batch order for the previously announced cannabinoid based inhalation medicine for Asthma/COPD has been placed.
Cannabis Science Develops Inhalation Medication for Those Suffering Asthma/COPD via Nebulizer, Targets National Markets
IRVINE, Calif., July 29, 2016 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce they will release an inhalation medication for those suffering asthma/COPD for use in patient nebulizers.
Cannabis Science 2016 Growth Guidance; Project Briefs, Cash-Flow Projections, and Current Historic Cannabis Industry Advancements; Industry Growth Indicators
IRVINE, Calif., July 20, 2016 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to provide its future operations and growth guidance based on its current projects, cash-flow projections, and current historic market advancements.